About the Company
Nymox Pharmaceutical Corporation specializes in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the rapidly aging male population in developed economies. The Company's lead drug candidate for benign prostatic hyperplasia (BPH) Fexapotide Triflutate (FT) has completed Phase 3 development in more than 70 clinical centers in the United States, involving more than 1700 patients during the entire clinical development program. Currently, the Company will soon be filing for approval in major economies around the world, including the United States and Europe.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $NYMX News
Nymox Pharmaceutical Corp NYMXF
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Nymox Pharmaceutical Corporation (NYMXF)
IRVINE, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets - NYMXF) is pleased to report that the Bahamas Supreme Court has issued a formal ...
Nymox Reports Victory in Bahamas Litigation Against Terminated Ex-Employees – Court Awards Costs and Damages
IRVINE, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets - NYMXF) is pleased to report that the Bahamas Supreme Court has issued a formal ...
Forecasting The Future: 11 Analyst Projections For Ultragenyx Pharmaceutical
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $82.55, along ...
New Suit - Patent
Teva Pharmaceutical Industries, an Israeli multinational pharmaceutical company, was hit with a patent infringement lawsuit on April 4 in Delaware District Court. The court action, asserting six ...
Protect Pharmaceutical Corp.
Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total ...
Nymox Reports Victory in Bahamas Litigation Against Terminated Ex-Employees – Court Awards Costs and Damages
IRVINE, Calif., March 27, 2024 (GLOBE NEWSWIRE) — Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets – NYMXF) is pleased to report that the Bahamas Supreme Court has issued a formal Order ...
Nymox Pharmaceutical Corporation (NYMXF)
*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Nymox Reports Victory in Bahamas Litigation Against Terminated Ex-Employees - Court Awards Costs and Damages
This is the first of more than one action by and between the Company and Randall Lanham, (former General Counsel for Nymox), Chris Riley, (former short-term CFO), Richard Cutler (former external ...
Nymox Pharmaceutical Corporation: Nymox Reports Victory in Bahamas Litigation Against Terminated Ex-Employees - Court Awards Costs and Damages
Zeit Aktuelle Nachrichten 28.03. NYMOX PHARMACEUTICAL CORP - 6-K, Report of foreign issuer 27.03. 'Transparent mischief' and 'malfeasances' no more: Nymox's legal battle in the Bahamas comes to a ...
Loading the latest forecasts...